Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Completing Time-Limited Therapy

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

Edward Ratner, MD – Patient

As I finish my year-long, time-limited treatment for chronic lymphocytic leukemia (CLL), I have two questions:  When do I celebrate?  and  What do I call myself?


I do have reasons to celebrate!  After about 7 years of Watch and Wait (and worry), I started treatment with obinutuzumab (Gazyva) and venetoclax (Venclexta). I have previously written about the decision process for initial treatment in this article.  That was based upon my experiences in the months leading up to starting therapy.  Now, about a week after taking my last dose of venetoclax, it is a good time to again reflect.

Today, I can celebrate feeling better than I have in a long time.  The initial month of obinutuzumab almost completely eliminated a variety of vague symptoms I had endured for several years, such as abdominal pains at night and leg cramps.  Unfortunately, within days after starting venetoclax, I developed a productive cough that kept me up at night, associated with a runny and stuffed nose.  A dose reduction after two months helped, but I barely tolerated the cough for the rest of the year.  Standard treatments for allergic rhinitis (antihistamine and nasal steroids) didn’t help.  Today, off venetoclax (and after several days of a different type of nasal spray, ipratropium), I would describe the cough and nasal symptoms as mild and improving.  So, I could celebrate, but maybe I should wait until the cough resolves completely.

Statistically, my prognosis is very good.  Research on initial treatment with obinutuzumab and venetoclax has shown a large majority of patients with CLL will have little or no detectable disease for at least 5 years, for those who completed a full year of venetoclax.  Even with the dose reduction I required, odds are very good that I have achieved a full remission, by at least some definitions.  So, I could celebrate completing the year on treatment, but maybe I should wait until next week when I find out the results of my end-of-treatment flow cytometry, to see how few CLL cells might remain. 

My third alternative is to celebrate every day that I can enjoy my family, friends, and activities that bring me pleasure and fulfillment.  Completing a year-long treatment process brings me closer to that place in my journey.


Since my diagnosis of CLL, I have progressively expanded the circle of people to support me in my journey.  For the first several years, that included only my wife and a single close friend.  Even after I began facilitating a local support group, few other people knew of my diagnosis.  Treatment led me to need, and feel comfort from, support from most people I interact with regularly.  Now that I have finished the planned course of treatment, I would like to label myself in some way.  Yet the common terms used for those who have been on such a cancer journey seem inappropriate for me.  I don’t feel like a “survivor,” “victim,” or “sufferer.”  Each of those terms seem more passive than my experience.  I cannot consider myself cured, only at best at the beginning of long-term remission.  I invested much of about 20 days to my appointments and treatment over the year.  That included my first ever, and fortunately short and uneventful, hospitalization.  I had both the cough and a few weeks of intermittent diarrhea, but don’t look back and say I suffered.  I would describe my experience as time-consuming and irritating.  I also didn’t travel far (except the 90 minutes to Mayo Clinic), mostly due to anxiety about getting sick far from home or catching COVID.  I simply got through the year, continuing to work from home, taking walks almost every day (regardless of weather) and spending time with my 3-year-old grandson.

I have looked for a word to now describe myself in this journey.  I don’t like the common words used by those who undergo traditional cancer treatments, such as chemotherapy, radiation, or surgery, but haven’t found one for those of us who have endured a different set of challenges with targeted immunotherapy.  I have spent a year thinking about my CLL every day as I took my pills, and almost every night as I sat up to cough.  I also counted the days until I was done, but remained uncertain whether the treatment would be successful at achieving remission. There may be no good single word for the complexity of this journey, which continues.


I have much to celebrate, and plan to in a variety of ways. While I do that in the coming days, weeks, and maybe months (or daily for the rest of my life), I will continue to consider if there is a good label for my experience and response.  Regardless, I have new confidence in my strength and endurance, and will use that for whatever comes next.    

Dr. Ratner is a 67-year- old geriatrician in Minnesota who serves as a support group facilitator for the CLL Society.  He has contributed several other articles to the CLL Society website.